Knowledge today. Answers sooner. Hope for all.
Every child deserves the earliest possible answer.
Early Answers Foundation is building a global alliance to make responsible genetic and genomic testing available earlier — beginning at birth and prioritizing children whose health may depend on it.
We unite rare-disease organizations, families, scientists, healthcare professionals, policymakers, public health systems, insurers and advocates around one focused objective:
Give every family access to the best available knowledge, at the earliest responsible moment.
The best available science, at the earliest responsible moment, for every child and family who chooses it.
Our Mission & Vision
Unite the rare-disease community to make earlier genetic answers available to every child who may benefit.
Mission
Early Answers Foundation unites rare-disease organizations, families, healthcare professionals, researchers, health systems, payers and public voices to make the best available genetic and genomic testing accessible at the earliest responsible moment in life.
Beginning with newborns and seriously ill children, we build the scientific, human and economic case for health-system adoption. We work to move appropriate testing from research and exceptional access into responsible, equitable care — and use what we learn to advance diagnosis, prevention, treatment and cures worldwide.
Vision
- We envision a world where every child has the opportunity to begin life with the best knowledge science can responsibly provide.
- A world where a family’s access to answers does not depend on geography, income, insurance, race or circumstance.
- A world where every significant result leads to confirmation, counselling, appropriate care and a clear plan — and where responsibly governed knowledge helps improve the future for every family that follows.
Our Core Belief
An early answer can change an entire life.
Some children are born with serious genetic conditions that cannot be seen and may not cause symptoms until a medical crisis occurs.
Genomic science is creating the ability to identify hundreds of these conditions earlier. Yet access remains inconsistent, fragmented or unavailable. In many places, advanced testing is offered only after a child becomes critically ill — or after a family has spent years searching for an explanation.
We believe families should not have to wait for a crisis, an irreversible injury or a second tragedy before the right question is asked.
Early Answers Foundation exists to help health systems ask that question sooner.
Hundreds of serious genetic conditions are being evaluated for genomic newborn screening — the UK Generation Study examines 200+, GUARDIAN examines about 450, and the developing BEACONS-NBS research list contains 777.
Our Story
Abigail and Molly are our reason.
Abigail died unexpectedly in her sleep.
At the time, her illness had been understood as sepsis. Genetic testing was not performed, and her underlying PPA2 deficiency — a rare mitochondrial condition associated with sudden cardiac arrest — was not identified.
Without that genetic answer, the family did not know that another child might be at risk. They did not have the opportunity to pursue family testing, specialist care, condition-specific precautions or an informed emergency plan.
Molly later died before the family had access to the knowledge that might have changed the precautions, preparation and care available to her.
Earlier knowledge cannot prevent every tragedy. But it can give families and healthcare teams options they would not otherwise have: surveillance, precautions, treatment when available, emergency planning and the ability to make informed decisions.
Abigail and Molly’s story is why early answers cannot depend on luck, geography, a crisis or a second loss.
Their lives are the reason we are building a better system.
The Problem
The knowledge exists. The system has not caught up.
Traditional newborn screening has saved lives for decades, but it generally examines a limited number of conditions.
Genomic technology can investigate many more serious genetic conditions at once. Research programs around the world are now studying how expanded genomic newborn screening can be used safely, accurately and responsibly.
But several gaps remain:
- Research has not yet become routine care.
- Screening policies differ widely between jurisdictions.
- Testing may be unavailable or denied by public systems and insurers.
- Healthcare professionals may lack genomic education and clear referral pathways.
- Families may receive results without adequate counselling or follow-up.
- Many rare-disease organizations work separately despite sharing common barriers.
- Genetic research and reference data do not adequately represent every population.
- Many lower-resource health systems lack access to even basic newborn screening.
- Evidence about outcomes and total system costs is not assembled into one compelling case.
No single rare-disease organization can change these systems alone.
Together, we can.
The Early Answers Alliance
Many conditions. One shared barrier. One stronger voice.
The Early Answers Alliance will bring together organizations representing genetic and rare conditions that could benefit from earlier recognition.
Each organization brings distinct expertise, lived experience and a dedicated community. The Alliance gives those communities a shared platform from which to advocate for earlier testing and better care.
Who we bring together
Rare-disease organizations
Condition-specific foundations and patient organizations provide scientific knowledge, family experience and trusted community relationships.
Families and people with lived experience
Families show what delayed answers cost — and what earlier information can make possible.
Healthcare professionals and researchers
Clinicians, scientists, genetic counsellors, laboratories and quality experts help define what is accurate, actionable and ready for responsible implementation.
Health systems and payers
Government-funded health systems and private insurers determine whether testing moves from research into accessible care.
Policymakers and public-health leaders
Public leaders can establish the policies, standards, funding and protections required for responsible adoption.
Public figures and advocates
Celebrities, athletes, artists and other public voices affected by rare disease can bring urgency and visibility to a problem that is too often unseen.
Global partners
Locally led organizations and healthcare leaders help ensure that programs reflect each country’s needs, priorities, resources and culture.
Our Theory of Change
One alliance. One evidence base. One coordinated argument.
Unite
Bring rare-disease communities and their allies together around shared principles and objectives.
Listen
Gather family experiences, clinical expertise, research findings and information about existing barriers.
Build the evidence
Create a credible scientific, ethical, quality and economic case for earlier testing.
Mobilize
Equip alliance members, public figures and advocates with coordinated messages, evidence and practical campaign tools.
Change systems
Work with governments, public health programs, insurers and healthcare leaders to fund and implement appropriate testing.
Measure and improve
Track access, diagnostic performance, follow-up, outcomes, costs and unintended consequences — and continuously improve the system.
Quality Is in Our DNA
A continuous-improvement approach to healthcare
Find sooner. Act sooner. Learn faster. Improve continuously.
Early Answers Foundation is grounded in the principles of quality and Kaizen: understand the system, identify risks as early as possible, learn from every result and continuously improve.
Identify
Use the best validated screening or diagnostic approach at the earliest appropriate time.
Confirm
Connect screening results with qualified clinical assessment and confirmatory testing.
Act
Provide families and healthcare teams with clear care pathways, precautions, treatment options and emergency information where available.
Learn
With meaningful consent and strong privacy protections, use responsibly governed information to improve understanding and research.
Improve
Continuously update screening criteria, clinical pathways, professional education and health policy as evidence evolves.
A test alone is not a complete system. Quality requires the entire pathway to work.
Our Five Workstreams
How we turn shared purpose into system change
1Alliance Building
Build a coordinated international network of rare-disease organizations, families, professionals, researchers and public advocates. The Foundation will help alliance members:
- Share expertise and resources
- Develop common policy objectives
- Coordinate campaigns
- Identify shared access barriers
- Present a stronger collective voice
- Preserve each organization’s individual identity and mission
2Policy and Payer Change
Create evidence-based proposals for both publicly funded and insurance-funded health systems.
For publicly funded systems
- Population health
- Equitable access
- Clinical outcomes
- Responsible use of public resources
- National or regional standards
- Long-term health-system value
For insurance-funded systems
- Medical necessity
- Earlier diagnosis
- Avoiding duplicative investigations
- Reducing preventable hospital utilization
- More informed care decisions
- Long-term clinical and economic value
We will work toward coverage policies that are transparent, consistent and based on current evidence.
3Professional Readiness
Testing can only improve care when professionals know when to use it and how to respond. We will support:
- Genomic education for healthcare professionals
- Clear testing and referral criteria
- Genetic counselling capacity
- Interpretation of results
- Condition-specific care pathways
- Emergency protocols where evidence supports them
- Continuing education as the science changes
4Science, Data and Research
Earlier answers can produce knowledge that supports the next generation of care. With informed consent, ethical oversight, privacy protections and appropriate community governance, aggregated knowledge may help researchers:
- Understand natural histories of rare conditions
- Recognize symptoms and risks earlier
- Improve screening accuracy
- Develop better emergency and care protocols
- Identify potential treatments and preventive strategies
- Recruit appropriate participants for research
- Improve representation in genomic reference data
- Accelerate therapeutic and cure development
The people and communities who contribute data should be respected as partners and should share in the benefits created from it.
5Global Equity
We seek progress in both established and lower-resource healthcare systems.
In countries where genomic newborn screening is being studied, we will advocate for responsible movement from evidence to implementation. In countries where basic screening remains limited, we will support locally led efforts to:
- Select appropriate priority conditions
- Build laboratory capacity
- Train professionals
- Develop referral and follow-up pathways
- Connect screening to available treatment
- Establish sustainable financing
- Expand programs as local capacity grows
The objective is not to export one system everywhere. It is to help local leaders build safe, sustainable programs suited to their communities.
The Case for Earlier Testing
Why early answers matter
The human case
A delayed or missed diagnosis can leave families without an explanation, an appropriate care plan or knowledge about risks to other family members.
Every child’s life has immeasurable value. The loss of a child devastates a family, affects an entire community and represents a loss that society carries forward.
The scientific case
Earlier recognition may create opportunities for monitoring, treatment, preventive measures or emergency preparation before a crisis occurs.
Even when no treatment currently exists, an accurate diagnosis can end an unnecessary search, inform care, connect families with condition-specific support and make appropriate research possible.
The quality case
A health system should identify serious risk at the earliest point where reliable detection and meaningful action are possible.
The goal is not indiscriminate testing. It is the right test, for the right conditions, at the right time, connected to the right response.
The economic case
Delayed diagnosis can involve repeated consultations, investigations, emergency visits and hospital admissions.
Evidence from selected groups — particularly critically ill infants — suggests earlier genomic diagnosis can improve care and may reduce avoidable costs. The Foundation will help build stronger evidence across different populations and health systems.
We will measure value rather than assume it.
Our Policy Ask
Offer every family the opportunity for an earlier answer.
Early Answers Foundation calls on governments, health systems and insurers to create a responsible pathway toward expanded genomic newborn screening and earlier diagnostic genomic testing. That pathway should include:
- Voluntary, informed participation
- Evidence-based condition selection
- Transparent standards for actionability
- Accurate and validated testing
- Confirmatory diagnostics
- Genetic counselling
- Condition-specific medical pathways
- Emergency guidance when appropriate
- Privacy and responsible data governance
- Equitable access
- Continuous measurement and improvement
- Sustainable funding
- International collaboration
Take Action
Every voice makes the case stronger.
-
Rare-disease organizations
Add your condition, expertise and community to a united case for earlier answers.
Join the Alliance -
Families
Share your experience and help decision-makers understand the consequences of delayed or missing answers.
Share Your Story -
Healthcare and research professionals
Help define scientific readiness, actionability, clinical pathways and responsible implementation.
Contribute Your Expertise -
Policymakers, health systems and insurers
Work with us to evaluate evidence and design responsible implementation pathways.
Start a Policy Conversation -
Public figures and campaigners
Use your platform to bring rare disease and early genetic answers into public view.
Become an Ambassador -
Supporters
Help build the research, alliances and public momentum required to change health systems.
Support the Foundation
The science is moving forward.
The system must move with it.
No family should face a preventable tragedy because a meaningful genetic answer was unavailable, delayed or overlooked.
By bringing hundreds of rare-disease communities together, we can build the evidence, public support and determination required to make earlier answers part of responsible healthcare.
Knowledge today. Answers sooner. Hope for all.